CLB Core Laboratories Inc

Price (delayed)

$12.45

Market cap

$571.26M

P/E Ratio

23.49

Dividend/share

$0.04

EPS

$0.53

Enterprise value

$713.64M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 44

Core Laboratories N.V. (Core Lab) is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. These products and services are directed toward ...

Highlights
CLB's debt is down by 8% YoY
CLB's equity is up by 4.4% YoY
The stock's price to earnings (P/E) is 41% less than its 5-year quarterly average of 39.6 but 3.5% more than its last 4 quarters average of 22.7
The quick ratio has decreased by 6% YoY but it has increased by 4% QoQ
CLB's net income is down by 18% year-on-year and by 16% since the previous quarter
Core Laboratories's EPS has decreased by 18% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of CLB

CLB stock price

How has the Core Laboratories stock price performed over time
Intraday
0.48%
1 week
9.69%
1 month
7.79%
1 year
17.45%
YTD
-22.33%
QTD
6.87%

Financial performance

How have Core Laboratories's revenue and profit performed over time
Revenue
$519.18M
Gross profit
$101.32M
Operating income
$47.8M
Net income
$24.35M
Gross margin
19.5%
Net margin
4.7%
CLB's net income is down by 18% year-on-year and by 16% since the previous quarter
CLB's net margin is down by 18% YoY and by 15% from the previous quarter
The operating margin has decreased by 12% YoY and by 11% from the previous quarter
Core Laboratories's operating income has decreased by 11% QoQ and by 11% YoY

Price vs fundamentals

How does CLB's price correlate with its fundamentals

Growth

What is Core Laboratories's growth rate over time

Valuation

What is Core Laboratories stock price valuation
P/E
23.49
P/B
2.1
P/S
1.1
EV/EBIT
15.04
EV/EBITDA
11.45
EV/Sales
1.37
The stock's price to earnings (P/E) is 41% less than its 5-year quarterly average of 39.6 but 3.5% more than its last 4 quarters average of 22.7
Core Laboratories's EPS has decreased by 18% YoY and by 16% from the previous quarter
The P/B is 51% below the 5-year quarterly average of 4.3 and 16% below the last 4 quarters average of 2.5
CLB's equity is up by 4.4% YoY
CLB's price to sales (P/S) is 39% lower than its 5-year quarterly average of 1.8 and 15% lower than its last 4 quarters average of 1.3

Efficiency

How efficient is Core Laboratories business performance
The return on equity has declined by 23% year-on-year and by 17% since the previous quarter
The ROA has contracted by 18% YoY and by 16% from the previous quarter
Core Laboratories's ROS has decreased by 12% YoY and by 11% from the previous quarter
The return on invested capital has declined by 10% since the previous quarter and by 5% year-on-year

Dividends

What is CLB's dividend history
DPS
$0.04
Dividend yield
0.32%
Payout ratio
7.5%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Core Laboratories financials performed over time
The total assets is 91% greater than the total liabilities
The total liabilities has decreased by 8% YoY
CLB's current ratio is down by 7% year-on-year but it is up by 3.4% since the previous quarter
CLB's debt is 39% less than its equity
The debt to equity has decreased by 10% YoY
CLB's debt is down by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.